Research Reports | Market Assessment
September 2021

Dry And Wet Age-Related Macular Degeneration – Landscape & Forecast – Disease Landscape & Forecast

The wet age-related macular degeneration (AMD) therapy market has long been dominated by three VEGF inhibitors: Roche / Genentech / Chugai’s Avastin, Roche / Genentech / Novartis’s Lucentis, and Regeneron / Bayer HealthCare / Santen’s Eylea. Competition was expected to increase with the U.S. launch of Novartis’s Beovu in October 2019, but safety concerns have slowed Beovu’s uptake. Nevertheless, the mainstay anti-VEGF therapies will face competition from the growing number of therapies for wet AMD in the late-stage pipeline, including biosimilar agents. In contrast to wet AMD, the management of dry AMD is limited because no prescription therapies are approved for this large subpopulation. Despite recent setbacks in the clinical development of some late-stage dry AMD therapies, other agents are progressing, increasing the likelihood that an effective therapy may soon emerge.

QUESTIONS ANSWERED

  • How will the wet AMD treatment algorithm change as new products launch? What impact has the COVID-19 pandemic had on the wet AMD therapy market?
  • To what extent will late-stage therapies such as Roche’s ranibizumab port delivery system and faricimab capitalize on the need for therapies with longer dosing intervals than those currently offered?
  • How receptive are retinal specialists to novel gene therapy approaches, to biosimilar agents for wet AMD, and to emerging therapies for GA?

PRODUCT DESCRIPTION

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.

Primary research: 31 country-specific interviews with thought-leading retinal specialists. Supported by survey data collected for this and other Clarivate research.

Epidemiology: Total prevalence of late AMD by country, segmented by GA and wet AMD subpopulations, including diagnosed and drug-treated rates.

Forecast: Ten-year, annualized, drug-level sales and patient share of key GA and wet AMD therapies through 2030, segmented by brands / biosimilars and epidemiological subpopulations.

Emerging therapies: Phase III / PR: 11 drugs; Phase II: 14 drugs; coverage of select Phase I products.

SOLUTION ENHANCEMENT

Disease Landscape & Forecast will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.

Table of contents

  • Dry And Wet Age-Related Macular Degeneration - Landscape & Forecast - Disease Landscape & Forecast
    • Key Updates
      • Q3 2021
        • September 2021
        • July 2021
      • Q2 2021
        • June 2021
        • May 2021
        • April 2021
      • Q1 2021
        • March 2021
        • February 2021
        • January 2021
      • Q4 2020
        • December 2020
      • Q3 2020
        • September 2020
      • Q2 2020
        • May 2020
    • Key Findings
      • Dry and Wet Age-Related Macular Degeneration - Key Findings - December 2020
        • May 2020
    • Market Outlook
      • Key Findings
        • Market Share of Drug Classes for AMD: 2019
        • Market Share of Drug Classes for AMD: 2029
        • Dry and Wet AMD SWOT Analysis
      • COVID-19: Areas of Potential Forecast Impact
        • Market Drivers and Constraints
          • What Factors Are Driving the Market for AMD?
          • What Factors Are Constraining the Market for AMD?
          • Major-Market Sales and Treated Patients in AMD: 2019-2029
          • Major-Market Brand and Biosimilar Sales and Market Share for VEGF Inhibitors in Wet AMD: 2019-2029
          • Market Share and Share of Treated Patients for AMD by Region: 2019-2029
        • Drug Class-Specific Trends
          • Patient Share of VEGF Inhibitors in Wet AMD in the United States: 2019-2029
          • Patient Share of VEGF Inhibitors in Wet AMD in Europe: 2019-2029
          • Patient Share of VEGF Inhibitors in Wet AMD in Japan: 2019-2029
          • Major-Market Sales of VEGF Inhibitors in Wet AMD: 2019-2029
          • Patient Share of Faricimab in Wet AMD in the Major Markets: 2019-2029
          • Major-Market Sales of Faricimab in Wet AMD: 2019-2029
          • Sales of Complement System Inhibitors in GA in the United States: 2019-2029
          • Patient Share of Complement System Inhibitors in GA in the United States: 2019-2029
          • Sales of Complement System Inhibitors in GA in Europe: 2019-2029
          • Patient Share of Complement System Inhibitors in GA in Europe: 2019-2029
      • Forecast
        • Market Forecast Downloads
        • Market Forecast Assumptions u2013 Dry and Wet Age-Related Macular Degeneration (2019-2029) u2013 November 2020
        • Market Forecast Dashboard - Dry and Wet Age-Related Macular Degeneration (2019-2029) - November 2020
      • Etiology and Pathophysiology
        • Disease Overview
          • Pathophysiology
            • Disease Classifications
            • Anatomy of the Eye
            • Pathology
          • Etiology
            • Mechanisms Associated with AMD Pathogenesis
          • Risk Factors
            • Genetic Risk Factors
            • Genetic Markers Associated with AMD
            • Other Risk Factors
            • Demographic and Environmental Risk Factors Associated with AMD
          • Key Pathways and Drug Targets
            • Potential Drug Targets for AMD
        • Epidemiology
          • Key Findings
            • Epidemiology Populations
              • Disease Definition
              • Methods
              • Sources Used for Total Prevalent Cases of Late AMD
              • Total Prevalent Cases of Late AMD: 2019-2029 (thousands)
              • Disease Definition
              • Methods
              • Sources Used for Total Prevalent Cases of GA and Wet AMD
              • Total Prevalent Cases of GA and Wet AMD: 2019-2029
              • Diagnosed Prevalent Cases of Wet AMD: 2019-2029
              • Diagnosed Prevalent Cases of GA: 2019-2029
              • Drug-Treated Wet AMD Cases: 2019-2029
              • Drug-Treated GA Cases: 2019-2029
          • Current Treatment
            • Key Findings
              • Treatment Goals
                • Key Endpoints Used in Clinical Trials for AMD
                • Imaging Techniques Used in Evaluating AMD
              • Key Current Therapies
                • Overview
                • Mechanism of Action of Key Current Drug Classes Used for Wet AMD
                • Current Treatments Used for Wet AMD
                • Dosing Regimens as Indicated in the Labels of Key VEGF Inhibitors Approved for the Treatment of Wet AMD by Region
                • Commonly Used Treatment Regimens for VEGF Inhibitors in Wet AMD in Clinical Practice
                • Market Events Impacting the Use of Key Current Therapies in AMD
                • Advantages and Disadvantages of Lucentis
                • Expert Insight on Lucentis
                • Advantages and Disadvantages of Eylea
                • Expert Insight on Eylea
                • Advantages and Disadvantages of Avastin
                • Expert Insight on Avastin
                • Advantages and Disadvantages of Macugen
                • Advantages and Disadvantages of Beovu
                • Key Results from Select Clinical Trials Investigating Beovu for the Treatment of Wet AMD
                • Ongoing Clinical Development of Beovu
                • Key Ongoing Clinical Trials of Beovu in the Treatment of Wet AMD
                • Expert Insight on Beovu
                • Advantages and Disadvantages of Visudyne / Photodynamic Therapy
              • Medical Practice
                • Overview
                • Country-Specific AMD Treatment Guidelines
                • Factors Influencing Drug Selection in Wet AMD
                • Treatment Decision Tree for AMD: United States
                • Treatment Decision Tree for AMD: Europe
                • Treatment Decision Tree for AMD: Japan
            • Unmet Need Overview
              • Current and Future Attainment of Unmet Needs in AMD
              • Top Unmet Needs in AMD: Current and Future Attainment
              • Expert Insight: Unmet Need in AMD
            • Emerging Therapies
              • Key Findings
                • Pipeline Trends in AMD
              • Key Emerging Therapies
                • Key Therapies in Development for AMD
                • Estimated Launch Dates of Key Emerging Therapies for the Treatment of AMD
                • Ranibizumab PDS Profile
                • Analysis of the Clinical Development Program for the Ranibizumab PDS
                • Key Development Milestones for the Ranibizumab PDS in the Treatment of Wet AMD
                • Expert Insight: Ranibizumab PDS
                • Expectations for Launch and Sales Opportunity of Ranibizumab PDS in Wet AMD
                • Likely Uses of Ranibizumab PDS for the Treatment of Wet AMD
                • Conbercept Profile
                • Analysis of the Clinical Development Program for Conbercept
                • Key Development Milestones for Conbercept in the Treatment of Wet AMD
                • Expert Insight: Conbercept
                • Expectations for Launch and Sales Opportunity of Conbercept in Wet AMD
                • Likely Uses of Conbercept for the Treatment of Wet AMD
                • ONS-5010 Profile
                • Analysis of the Clinical Development Program for ONS-5010
                • Key Development Milestones for ONS-5010 in the Treatment of Wet AMD
                • Expert Insight: ONS-5010
                • Expectations for Launch and Sales Opportunity of ONS-5010 in Wet AMD
                • Likely Uses of ONS-5010 for the Treatment of Wet AMD
                • High-Dose Aflibercept Profile
                • Analysis of the Clinical Development Program for High-Dose Aflibercept
                • Key Development Milestones for High-Dose Aflibercept in the Treatment of Wet AMD
                • Expectations for Launch and Sales Opportunity of High-Dose Aflibercept in Wet AMD
                • Likely Uses of High-Dose Aflibercept for the Treatment of Wet AMD
                • Expert Insight: High-Dose Aflibercept
                • KSI-301 Profile
                • Analysis of the Clinical Development Program for KSI-301
                • Key Development Milestones for KSI-301 in the Treatment of Wet AMD
                • Expert Insight: KSI-301
                • Expectations for Launch and Sales Opportunity of KSI-301 in Wet AMD
                • Likely Uses of KSI-301 for the Treatment of Wet AMD
                • OPT-302 Profile
                • Key Ongoing Clinical Trials of OPT-302 in the Treatment of Wet AMD
                • Analysis of the Clinical Development Program for OPT-302
                • Expert Insight: OPT-302
                • Expectations for Launch and Sales Opportunity of OPT-302 in Wet AMD
                • Faricimab Profile
                • Analysis of the Clinical Development Program for Faricimab
                • Key Development Milestones for Faricimab in the Treatment of Wet AMD
                • Expert Insight: Faricimab
                • Expectations for Launch and Sales Opportunity of Faricimab in Wet AMD
                • Likely Uses of Faricimab for the Treatment of Wet AMD
                • Pegcetacoplan Profile
                • Analysis of the Clinical Development Program for Pegcetacoplan
                • Key Development Milestones for Pegcetacoplan in the Treatment of GA
                • Expert Insight: Pegcetacoplan
                • Expectations for Launch and Sales Opportunity of Pegcetacoplan in GA
                • Likely Uses of Pegcetacoplan for the Treatment of GA
                • Zimura Profile
                • Analysis of the Clinical Development Program for Zimura
                • Key Development Milestones for Zimura in the Treatment of GA
                • Expert Insight: Zimura
                • Expectations for Launch and Sales Opportunity of Zimura in GA
                • Likely Uses of Zimura for the Treatment of GA
                • ALK-001 Profile
                • Analysis of the Clinical Development Program for ALK-001
                • Key Development Milestones for ALK-001 in the Treatment of Wet AMD
                • Expectations for Launch and Sales Opportunity of ALK-001 in Wet AMD
                • Expert Insight: ALK-001
                • RGX-314 Profile
                • Key Ongoing Clinical Trials of RGX-314 in the Treatment of Wet AMD
                • Analysis of the Clinical Development Program for RGX-314
                • Expert Insight: RGX-314
                • Expectations for Launch and Sales Opportunity of RGX-314 in Wet AMD
                • Select Cell-Based Therapy Profiles
                • Expert Insight: Cell-Based Therapies
              • Early-Phase Pipeline Analysis
                • Select Compounds in Early-Phase Development for AMD
            • Access and Reimbursement Overview
              • Region-Specific Reimbursement Practices
                • Key Market Access Considerations in Wet AMD: United States
                • General Reimbursement Environment: United States
                • Key Market Access Considerations in Wet AMD: EU5
                • General Reimbursement Environment: EU5
                • Key Market Access Considerations in Wet AMD: Japan
                • General Reimbursement Environment: Japan
              • Looking for More?
            • Appendix
              • Key Abbreviations Related to Dry and Wet AMD
              • Brands, Marketers, and Generic Availability of Key Therapies for AMD by Market
              • Dry and Wet AMD Bibliography
          Andrea Witt, Ph.D.
          Andrea Witt, Ph.D.

          Andrea S. Witt, Ph.D., is Therapy Leader of the Central Nervous System and Ophthalmology Disorders Portfolio at Clarivate, where she oversees a team of Business Insights Analysts and Senior Directors responsible for market research encompassing Neurology, Psychiatry, Pain, and Ophthalmology.

          Her interests beyond specific CNS indications included the market potential for neuroprotectants and the impact of biomarkers on CNS markets. Dr. Witt’s research, analysis, and commentaries have appeared in Barron’s, Pharmaceutical Executive, PharmaVoice, Nature Medicine, and CNBC. Dr. Witt’s previous experience includes 10 years of scientific research conducted on neurodegenerative disorders at Harvard Medical School/Brigham and Women’s Hospital, Duke University, and the University of Texas-Southwestern Medical Center, where she earned her Ph.D. degree.

          Emma McFadden, Ph.D.
          Emma McFadden, Ph.D.

          Emma McFadden, Ph.D., is a director on the CNS/Ophthalmology Disorders team at Clarivate. Her focus is on ophthalmic indications, such as age-related macular degeneration, diabetic retinopathy, and diabetic macular edema, although she has authored reports in a number of other indications, including multiple sclerosis and epilepsy. Dr. McFadden earned a B.A. in neuroscience and a Ph.D. in biochemistry from Trinity College in Dublin.

           

          Login to access report
          Back to all Market Assessment reports
          Login to access report

          launch Related Market Assessment Reports